• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $3,802 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-174 Mln

Amicus Therapeutics Inc. (FOLD) Share Price

$13.46

As on 04-Mar-2024 16:00 EST

up-down-arrow $0.171.28%

  • Prev Close info

    $13.29

  • Day's Openinfo

    $13.29

  • Today's Highinfo

    $13.49

  • Today's Lowinfo

    $12.99

  • Today's Volumeinfo

    1,528,710

  • 52 Week rangeinfo

    $9.70 - 14.57

Please wait...

Amicus Therapeutics Inc. (FOLD) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Amicus Therapeutics (FOLD)
-5.14 8.20 19.96 6.83 8.08 -0.67 18.01
S&P BSE Sensex*
1.99 2.21 6.99 23.19 13.16 15.36 13.26
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 04-Mar-2024  |  *As on 05-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Amicus Therapeutics (FOLD)
16.22 5.71 -49.98 137.06 1.67 -33.28 189.54
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Amicus Therapeutics Inc. (FOLD) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Amicus Therapeutics Inc. (FOLD)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Amicus Therapeutics Inc. (FOLD)

        Executive Chairman

        Mr. John F. Crowley

        CEO, President & Director

        Mr. Bradley L. Campbell M.B.A.

        Headquarters

        Philadelphia, PA

        FAQs for Amicus Therapeutics Inc. (FOLD)

        The total asset value of Amicus Therapeutics Inc. (FOLD) stood at $ 934 Mln as on 30-Sep-23

        The share price of Amicus Therapeutics Inc. (FOLD) is $13.46 (NASDAQ) as of 04-Mar-2024 16:00 EST. Amicus Therapeutics Inc. (FOLD) has given a return of 8.08% in the last 3 years.

        Amicus Therapeutics Inc. (FOLD) has a market capitalisation of $ 3,802 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Amicus Therapeutics Inc. (FOLD) is 28.54 times as on 29-Feb-2024, a 8.58% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Amicus Therapeutics Inc. (FOLD) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Amicus Therapeutics Inc. (FOLD) and enter the required number of quantities and click on buy to purchase the shares of Amicus Therapeutics Inc. (FOLD).

        Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Address: 3675 Market Street, Philadelphia, PA, United States, 19104

        The CEO & director of Mr. John F. Crowley. is Amicus Therapeutics Inc. (FOLD), and CFO & Sr. VP is Mr. Bradley L. Campbell M.B.A..

        The promoters of Amicus Therapeutics Inc. (FOLD) have pledged 0% of the total equity as on Sep-23.

        Amicus Therapeutics Inc. (FOLD) Ratios
        Return on equity(%)
        -148.27
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        2.96
        Dividend yield(%)
        0

        No, TTM profit after tax of Amicus Therapeutics Inc. (FOLD) was $-174 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $3,802.04 Mln
        • Revenue (TTM)revenue-information $372.37 Mln
        • Earnings (TTM) earning-information $-173.61 Mln
        • Cash date-information $280.30 Mln
        • Total Debt info $454.29 Mln
        • Insider's Holding 0.68%
        • Liquidity liquidity High
        • 52 Week range week-range $9.70 - 14.57
        • Shares outstanding share-outstanding 293,246,016
        • 10 Years Aggregate:

          CFO: $-1,823.88 Mln

          EBITDA: $-1,828.48 Mln

          Net Profit: $-2,327.96 Mln

        About The Company

        • IPO Date 31-May-2007
        • Executive Chairman Mr. John F. Crowley
        • CEO, President & Director Mr. Bradley L. Campbell M.B.A.
        • Listing key-listing NASDAQ: FOLD
        • Country United States
        • Headquarters headquarters Philadelphia, PA
        • Website website https://amicusrx.com
        • Business

          Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults...  with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Address: 3675 Market Street, Philadelphia, PA, United States, 19104  Read more

        share-fund-plan-icon